Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana Maria Gonzalez-Angulo

Showing results (31-40 of 75) with videos related to

Pageof 8
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2008
Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancerDeann P Atchley, Constance T Albarracin, Adriana Lopez, et al.
Cancer|May 19, 2011
Bisphosphonates and pathologic complete response to taxane- and anthracycline-based neoadjuvant chemotherapy in patients with breast cancerMariana Chavez-Macgregor, Erika Brown, Xiudong Lei, et al.
The Breast Journal|December 13, 2012
Genotype in BRCA-associated breast cancersFunda Meric-Bernstam, Angelica M Gutierrez-Barrera, Jennifer Litton, et al.
Journal of Experimental & Clinical Cancer Research : CR|July 24, 2014
EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancerBisrat G Debeb, Yun Gong, Rachel L Atkinson, et al.
Clinical Breast Cancer|December 17, 2008
Using response to primary chemotherapy to select postoperative therapy: long-term results from a prospective phase II trial in locally advanced primary breast cancerAna Maria Gonzalez-Angulo, Ronald Walters, Kristine Broglio, et al.
Cancer|June 22, 2010
Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy: evaluating the effect of race/ethnicityMariana Chavez-Macgregor, Jennifer Litton, Huiqin Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 31, 2012
Biomarkers of response to Akt inhibitor MK-2206 in breast cancerTakafumi Sangai, Argun Akcakanat, Huiqin Chen, et al.
Cancer|January 31, 2006
Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapyBryan T Hennessy, Ana Maria Gonzalez-Angulo, Gabriel N Hortobagyi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2011
Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancerAmal Melhem-Bertrandt, Mariana Chavez-Macgregor, Xiudong Lei, et al.
Annals of Surgical Oncology|September 28, 2011
Triple-negative breast cancer is not a contraindication for breast conservationFarrell C Adkins, Ana Maria Gonzalez-Angulo, Xiudong Lei, et al.
Pageof 8

Showing results (31-40 of 75) with videos related to

Sort By:
Pageof 8
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2008
Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancerDeann P Atchley, Constance T Albarracin, Adriana Lopez, et al.
Cancer|May 19, 2011
Bisphosphonates and pathologic complete response to taxane- and anthracycline-based neoadjuvant chemotherapy in patients with breast cancerMariana Chavez-Macgregor, Erika Brown, Xiudong Lei, et al.
The Breast Journal|December 13, 2012
Genotype in BRCA-associated breast cancersFunda Meric-Bernstam, Angelica M Gutierrez-Barrera, Jennifer Litton, et al.
Journal of Experimental & Clinical Cancer Research : CR|July 24, 2014
EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancerBisrat G Debeb, Yun Gong, Rachel L Atkinson, et al.
Clinical Breast Cancer|December 17, 2008
Using response to primary chemotherapy to select postoperative therapy: long-term results from a prospective phase II trial in locally advanced primary breast cancerAna Maria Gonzalez-Angulo, Ronald Walters, Kristine Broglio, et al.
Cancer|June 22, 2010
Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy: evaluating the effect of race/ethnicityMariana Chavez-Macgregor, Jennifer Litton, Huiqin Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 31, 2012
Biomarkers of response to Akt inhibitor MK-2206 in breast cancerTakafumi Sangai, Argun Akcakanat, Huiqin Chen, et al.
Cancer|January 31, 2006
Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapyBryan T Hennessy, Ana Maria Gonzalez-Angulo, Gabriel N Hortobagyi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2011
Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancerAmal Melhem-Bertrandt, Mariana Chavez-Macgregor, Xiudong Lei, et al.
Annals of Surgical Oncology|September 28, 2011
Triple-negative breast cancer is not a contraindication for breast conservationFarrell C Adkins, Ana Maria Gonzalez-Angulo, Xiudong Lei, et al.
Pageof 8